Major progress in fighting pancreatic cancer, new medicine contracts tumors in most patients

Major progress in fighting pancreatic cancer, new medicine contracts tumors in most patients

Major progress in fighting pancreatic cancer, new medicine contracts tumors in most patients

A new experimental drug called daraxonsonsib is viewed as one of the most important advances in treating pancreatic cancer in recent decades, as the results of a new study have shown tumor contractions in most patients.

According to results presented this week in Barcelona, in the European-American cancer therapy symposium, the drug has also shown promising effects on cancer patients with advanced pancreatic cancer, which had spread to other organs.

3M Express sponsor

61 patients participated in the study. The results showed that 90 percent of the tumors stopped growing, while more than 60 percent contracted or disappeared. In about 8 percent of cases, tumors were no longer seen in CT scans.

A year after the treatment began, 76.6 percent of the patients were still alive. This figure is markedly higher compared to the average one – year survival of 40 to 45 percent reported in patients treated only by chemotherapy.

Oncologist Dr. Wungki Park, of the Sloan Kettering Cancer Center in New York, who presented the results, described the development as the closest to the recovery he has seen in patients with the disease.

The chief of the British organisation Cancer Research UK, Michelle Mitchell, also described this as a major breakthrough in treating pancreatic cancer, but stressed that more studies are needed to confirm the results.

Daraxonensib is produced by the American company Revolution Medicians and functions by blocking the KRAS protein, which plays an important role in the growth of cancer cells. CRAS’s mutations are found in almost all cases of pancreatic cancer.

This development is especially important because of aggressiveness. When pancreatic cancer spreads to other organs, long – term survival opportunities are very limited.

Despite promising results, however, researchers warn that complete recovery is still not possible. It remains to determine how long the drug can keep the disease under control when it will be approved for extensive use and how much it will cost.

Further information is needed to see if the deraxonrasib can be effective against other types of cancer.

The signal where the truth speaks before the news!

/Gazeta Sinjali/

Source Layer: Signal

Read more

Medon Berisha returns to training, ready to return to the field

Medon Berisha returns to training, ready to return to the field

The lung council can in many cases be treated with surgical surgery ( VIDEOS)

The lung council can in many cases be treated with surgical surgery ( VIDEOS)

Pian surgeon Sefedin the man separates from life

Pian surgeon Sefedin the man separates from life